Floatz logo

Dccr

Prader-Willi Syndrome

Soleno Therapeutics, Inc.Small moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Prader-Willi Syndrome cohort.

Asset / SponsorPhaseRating
Genotropin
Corporacion Parc Tauli
Phase 4BBB
Oxytocin
University Hospital, Toulouse
Phase 2/3BBB
Guanfacine
Maimonides Medical Center
Phase 4BB
Omnitrope
University Hospital, Toulouse
Phase 4BB
Tirzepatide
Grace Kim
Phase 4BB

View all 33 →

Same molecule, other indications

Dccr is also rated in:

severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiencyDormant
CCC
Indicative ·
53 / 100
View asset →
obesity due to prohormone convertase I deficiencyDormant
CCC
Indicative ·
53 / 100
View asset →
obesity due to SIM1 deficiencyDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →